Immune based prognostic biomarkers for multiple anticancer therapies in lung adenocarcinoma

Kritika Karri, Dhundy R. Bastola

Research output: Chapter in Book/Report/Conference proceedingConference contribution

1 Scopus citations

Abstract

Lung adenocarcinoma is the leading cause of cancer deaths in the United States. This subtype of lung cancer shows an average five-year survival rate of 15-17%, which is mainly due to late diagnosis and specific prognostic evaluation for therapy recommendation. There is an urgent need for developing reliable prognostic biomarkers to predict the success of the therapy and devise effective treatment strategies. In this study, we analyze gene expression data using RNA-seq from patients suffering from lung adenocarcinoma, who were subjected to one of four different anticancer therapies and demonstrated one of two-response phenotype post-therapy. We used gene set enrichment analysis to predict the outcome of multiple anticancer therapies based on host immune response. Results indicate the gene expression based study offers an avenue to short list putative-biomarkers for each anticancer therapy, which can be used for effective diagnostics and personalized treatment to improve therapeutic outcome in lung adenocarcinoma patients.

Original languageEnglish (US)
Title of host publicationProceedings - 2016 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2016
EditorsKevin Burrage, Qian Zhu, Yunlong Liu, Tianhai Tian, Yadong Wang, Xiaohua Tony Hu, Qinghua Jiang, Jiangning Song, Shinichi Morishita, Kevin Burrage, Guohua Wang
PublisherInstitute of Electrical and Electronics Engineers Inc.
Pages1120-1127
Number of pages8
ISBN (Electronic)9781509016105
DOIs
StatePublished - Jan 17 2017
Event2016 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2016 - Shenzhen, China
Duration: Dec 15 2016Dec 18 2016

Publication series

NameProceedings - 2016 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2016

Other

Other2016 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2016
CountryChina
CityShenzhen
Period12/15/1612/18/16

Keywords

  • Alkylating agents
  • Anti-angiogenesis
  • Anticancer Therapy
  • Antimetabolite
  • Biomarker
  • Complete Remission
  • Immune response
  • Lung adenocarcinoma
  • Mitotic inhibitors
  • Optimized model
  • Progressive Disease

ASJC Scopus subject areas

  • Genetics
  • Medicine (miscellaneous)
  • Genetics(clinical)
  • Biochemistry, medical
  • Biochemistry
  • Molecular Medicine
  • Health Informatics

Fingerprint Dive into the research topics of 'Immune based prognostic biomarkers for multiple anticancer therapies in lung adenocarcinoma'. Together they form a unique fingerprint.

Cite this